Table 2.
Weight loss combined medications under investigation.
| Drug | Average Weight Loss in Treatment Group versus Placebo Group | Side Effects | Clinical Trial Time Frame |
|---|---|---|---|
| GIP/GLP-1 Receptor Agonist [63] | −0.9 to −11.3 kg vs. −0.4 kg | Nausea, vomiting, diarrhea, decreased appetite | 26 weeks |
| GLP-1/Glucagon Receptor Agonists [71] | −2.4 ± 0.4 kg vs. −0.5 ± 0.6 kg | Mild nausea, discomfort at injection site | 4 weeks |
| SGLT2/GLP-1 Receptor Agonists [87] | −3.55 (−4.12 to −2.99) vs. −1.56 (−2.13 to −0.98) or −2.22 (−2.78 to −1.66) | Diarrhea, nausea, injection site nodules, urinary tract infections | 28 weeks |
| GLP-1 Receptor Agonist/Amylin Analogue [92] | −15.9 (SE 1.40) vs. −7.8 (SE 2.2) | Nausea (most common), vomiting, dyspepsia, decreased appetite | 20 weeks |
| GLP-1/GIP/Glucagon Receptor Agonists [93] 1 | −26.6% vs. −15.7% | - | 20 days |
1 Animal rodent/mice studies. SE: standard error.